Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Phase 2

Recruiting

Conditions: High Grade Glioma
CNS Tumor

Interventions: Drug: Entrectinib
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Carboplatin
Biological: G-CSF
Biological: Pegfilgrastim
Procedure: Surgery

First Posted Date: 2024-07-30

Last Posted Date: 2024-12-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 52

Registration Number: NCT06528691

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

Phase 3

Recruiting

Conditions: Multiple Myeloma
Hematopoietic Stem Cell Mobilization

Interventions: Drug: Etoposide
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Pegfilgrastim
Drug: G-CSF

First Posted Date: 2024-07-25

Last Posted Date: 2024-07-25

Lead Sponsor: The Affiliated People's Hospital of Ningbo University

Target Recruit Count: 99

Registration Number: NCT06520176

Locations: 🇨🇳
Dongyang People's Hospital, Dongyang, Zhejiang, China
🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳
The First Hospital of Jiaxing, Jiaxing, Zhejiang, China

and more 13 locations

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Phase 2

Not yet recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Polatuzumab vedotin
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Orelabrutinib
Drug: Venetoclax
Drug: Chidamide
Drug: Penpulimab
Drug: Lenalidomide

First Posted Date: 2024-07-24

Last Posted Date: 2024-07-24

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 528

Registration Number: NCT06516978

Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma

Phase 1

Not yet recruiting

Conditions: HPV-Related Squamous Cell Carcinoma
HPV-Related Cervical Squamous Cell Carcinoma
HPV-Related Vulvar Squamous Cell Carcinoma
HPV-Related Penile Squamous Cell Carcinoma
HPV-Related Vaginal Squamous Cell Carcinoma
HPV-Related Anal Squamous Cell Carcinoma
HPV-Related Head and Neck Cancer

Interventions: Biological: SCG142
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-07-17

Last Posted Date: 2024-07-17

Lead Sponsor: SCG Cell Therapy Pte. Ltd.

Target Recruit Count: 66

Registration Number: NCT06505551

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Phase 2

Recruiting

Conditions: Large B-cell Lymphoma

Interventions: Device: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
Genetic: cemacabtagene ansegedleucel
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-07-15

Last Posted Date: 2024-11-29

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 250

Registration Number: NCT06500273

Locations: 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
University of Louisville Health Brown Cancer Center, Louisville, Kentucky, United States

and more 25 locations